Sec. 21a-254a. Appointment of prescription drug monitoring working group. Membership.
Sec. 21a-254a. Appointment of prescription drug monitoring working group.
Membership. The Commissioner of Consumer Protection shall appoint a prescription
drug monitoring working group for the purpose of advising the commissioner on the
implementation of the electronic prescription drug monitoring program established pursuant to section 21a-254, including the adoption of regulations by the commissioner.
Such advice shall include, but not be limited to, recommendations on how to effectively
use the data collected pursuant to such program to detect fraud while protecting the
legitimate use of controlled substances. The working group shall include, but not be
limited to: (1) A physician, licensed pursuant to chapter 370, specializing in internal
medicine; (2) a board certified oncologist; (3) a person licensed to perform advanced
level nursing practice activities pursuant to subsection (b) of section 20-87a; (4) a representative from an acute care hospital licensed pursuant to chapter 368v; (5) a state police
officer appointed in accordance with section 29-4; (6) a municipal police chief; (7) a
representative from the Division of Criminal Justice; (8) a representative from a hospice
licensed by the Department of Public Health or certified pursuant to 42 USC 1395x; (9)
a pain management specialist, as defined in section 38a-492i; (10) a pharmacist licensed
pursuant to section 20-590, 20-591 or 20-592; and (11) a representative from the Department of Mental Health and Addiction Services.
(P.A. 06-155, S. 2.)